The presence of septal hypertrophy in hypertrophic cardiomyopathy (HCM) is common. To date, there has been no accepted classification of septal morphology in HCM. Furthermore, the possible relationship between septal morphology and clinical features of HCM is undefined.
Introduction
Hypertrophic cardiomyopathy (HCM) is a relatively common genetic disorder of the myocardium with a wide variability in anatomic and clinical characteristics. Despite differences in phenotypic expression, septal hypertrophy is commonly present in this disease.
1,2 Almost three decades ago, the gross configuration of the septum was linked to haemodynamic differences in patients with HCM. 2, 3 More recently, an association between septal morphology and the presence of a sarcomeric mutation by genotyping has been reported. 4, 5 These findings suggest that septal morphology in HCM may have clinical implications for the assessment and management of patients with HCM. To date, however, there have been no accepted, reproducible criteria for classifying septal morphologies in HCM despite the perception that they may be clinically relevant. We hypothesized that septal morphology may be associated with different clinical manifestations of HCM. Specifically, the objectives of this study were (i) to develop a simple, reproducible classification of septal morphology in HCM using echocardiography and (ii) to investigate possible associations between septal morphology and clinical characteristics, including left ventricular function and fibrosis as detected by late gadolinium enhancement (LGE) by cardiac magnetic resonance (CMR) imaging.
Methods

Patient population
Consecutive, unrelated, adult patients between 2002 and 2005 with HCM, defined by the presence of unexplained left ventricular hypertrophy (. 14 mm), 6 referred to a specialized clinic for evaluation and/or management of this condition, were offered enrolment into this study. Exclusion criteria were prior septal reduction therapy (either alcohol septal ablation or surgical myectomy), known coronary artery disease, a permanent pacemaker or implantable cardioverterdefibrillator (ICD), or other contraindication to CMR. Clinical data were reviewed for each subject, including baseline demographic characteristics, clinical status, and risk factors for sudden cardiac death (SCD) [the presence of extreme ventricular hypertrophy (. 30 mm), ventricular tachycardia (VT) on ambulatory Holter monitoring, abnormal blood pressure response during exercise, personal or family history of sudden death, and recurrent syncope]. 6 The protocol was approved by the Duke University Institutional Review Board. All patients provided written informed consent.
Septal morphology determination
Standard views were obtained using a Phillips Sonos 7500 Ultrasound System (Phillips Medical System, Bothell, WA, USA). Two-dimensional echocardiography in two standard transthoracic imaging views, the parasternal long-axis (LAX) and the apical four-chamber (A4) views, were utilized to determine septal morphology. Location and extent of septal hypertrophy were recorded at the basal-, mid-, and apicalseptum in the A4 view. Maximum basal wall thickness was also recorded in the LAX view. The basal septum was defined as the portion of the septum between the aortic annulus and the septal point closest to the anterior mitral valve (MV) leaflet at end-diastole in both LAX and A4 views. The remainder of the septum distal to the point of MV contact was divided in half into an apical-and midseptal portion in the apical four-chamber view.
With these echocardiographic measurements a simple algorithm ( Figure 1 ) was used to classify septal morphology into the following sub-groups: † Simple sigmoid: maximal septal wall thickness located in the basal septum by both LAX and A4 views. † Catenoid: maximal septal wall thickness in the mid-septum by A4 view. † Neutral: uniformly thickened septum, with a ratio of maximal septal wall thickness in each septal segment of ≥0.8 by the A4 view. † Apical: maximal septal wall thickness in the apical-septum by the A4 view.
Measurement of inter-observer variability
In order to measure the reproducibility of the septal classification scheme, a random sample of 20 transthoracic echocardiograms of patients with HCM seen at our centre in 2008 were reviewed. Septal morphologies were independently classified by two readers (A.T.T., Z.S.) using the algorithm outlined in Figure 1 . The kappa statistic was calculated to assess inter-observer variability.
Echocardiographic assessment
Left ventricular outflow tract (LVOT) gradients were determined using the modified Bernoulli equation at rest and during Valsalva manoeuvre. Diastolic function was graded using standard Doppler criteria, including tissue Doppler. 7, 8 Diastolic function was graded on a scale of 0 -3, with grade 0 ¼ normal, grade 1 ¼ impaired relaxation, grade 2 ¼ pseudonormal, and grade 3 ¼ restrictive filling. The mitral annular and anterior MV leaflet (AMVL) height were measured in the parasternal LAX view in early systole immediately following MV closure, as previously described. 9 The coaptation ratio of AMVL-to-total annular height was then calculated, with coaptation ratio ,0.5 representing an anterior displacement of the MV coaptation point. 10 Echocardiographic assessments were performed at a median of 0 days (interquartile range 0 -32 days prior) from the CMR examination.
Cardiac magnetic resonance imaging
CMR images were obtained using a 1.5-T scanner (Siemens Sonata) with a phased-array receiver coil. Steady-state-free-precession (SSFP) cine Figure 1 Algorithm for classification of septal morphology, using two-dimensional echocardiography in apical four-chamber (A4) and parasternal long-axis (LAX) views.
A.T. Turer et al.
images were acquired in multiple short-axis (every centimetre throughout the left ventricle) and three LAX views. Gadolinium contrast (0.15 mmol/kg gadoversetamide) was administered. CMR images were acquired after 10 min with a segmented inversion-recovery technique 11 in the identical views as cine-CMR. Inversion delay times were adjusted to null normal myocardium and were typically 270-350 ms. Presence and quantification of LGE was determined by two investigators (A.M.V., B.H.) blinded to both the clinical information and echocardiography results. Regional parameters were assessed with a 17-segment model as previously described in detail. 12 The myocardial borders on the short-axis cine images were planimetered and left ventricular volumes, ejection fraction, and mass (assuming density ¼ 1.05 g/cm 3 ) were determined. The extent of LGE was determined visually in our CMR core laboratory. Using Bland-Altman analysis, the intra-observer agreement for the extent of LGE was calculated in a random sample of 10 patients; the mean difference in measurements was 0.6% with a standard deviation of the differences of 2.2%. In a randomly selected sample of 10 study patients with LGE, the signal intensities of the region of scar and a region of normal myocardium were assessed. The mean signal intensity of the region of scar was higher by 6.6 standard deviations of normal region intensity (range: 2.9, 11.8). The extent of LGE was planimetered on the short-axis CMR images and expressed as a percentage of LV mass.
Statistical analysis
Continuous data are reported as mean (+standard deviation) or as median (25 -75th interquartile range) depending on satisfaction of the normality assumption. Comparisons of continuous variables between subgroups were performed using analysis of variance or the Kruskal-Wallis test. Fisher's exact test was used to compare dichotomous variables between groups.
In order to assess the relationship between ventricular morphologic parameters and the presence of hyperenhancement by CMR, univariate and multivariate logistic regression analysis was performed. LV mass index and maximum LV wall thickness by CMR, presence of a resting or provoked LVOT gradient over 30 mmHg, and a catenoid septal configuration were included as analysis variables. All statistical tests were two-tailed and P-values of ,0.05 were regarded as significant. Analyses were performed using SAS 9.1.3 with Enterprise Guide Version 4.
Results
Seventy-five patients were enrolled in this study. The baseline clinical characteristics of the study population are given in Table 1 
Clinical features
The clinical characteristics of the population stratified by septal morphology are shown in Table 1 . There were significant differences in the mean age of diagnosis of HCM (P ¼ 0.001), with an earlier age of symptom onset among patients with catenoid subtypes compared with simple sigmoid (P ¼ 0.0001). Almost half of the patients [36 of 75 (48%)] in the overall cohort had NYHA class 3 symptoms; more than half of patients (57%) with the catenoid morphology had these advanced symptoms.
Echocardiographic features
There were significant differences in location of maximal wall thickness between septal classifications ( Table 2) , as was expected given the definitions used to categorize the morphologies. Extreme septal hypertrophy (≥30 mm) was seen in seven patients (10%) of the entire cohort, all of whom were in the catenoid subgroup. Within the catenoid subtype, 15 of 46 (33%) demonstrated, in addition to the maximal septal wall thickness in the mid-septum, an added prominence in the basal septum in the LAX (i.e. subaortic) such that the maximal septal hypertrophy appeared to course from the basal anteroseptum infero-apically (see Supplementary data online, Figure S1 ). This complex sigmoid morphology resembled the simple sigmoid-based solely on the LAX but was easily distinguishable as catenoid by the A4, where the location of maximal septal wall thickness could be identified as being in the mid-septum, rather than below the aortic valve. There were no significant differences in the MV annular dimension or height of the MV coaptation point between septal subtypes. Similarly, there were no significant differences in the mean MV coaptation ratio between groups. As shown in Table 3 , the resting LVOT gradients differed among septal morphologies. Catenoid and neutral septal morphologies had high resting gradients which increased only modestly with provocation. In contrast, the simple sigmoid subtype had a modest resting gradient 31 mmHg Diastolic function also varied by septal morphology. Pseudonormal (grade 2) or restrictive filling (grade 3) patterns of diastolic dysfunction were more prevalent in patients with catenoid morphology (36% with grade 2 and 27% with grade 3) but uncommon in other septal configurations.
Inter-observer assessment of septal morphology
In the sample of HCM patients selected to evaluate the interobserver agreement for determining septal subtype, the distribution of septal morphologies was similar to that found in the study cohort. Catenoid subtype was the most common (11 of 
Cardiac magnetic resonance and late gadolinium enhancement
The subtypes of septal morphologies differed in CMR measurements of LV mass and the presence and extent of LGE, as shown in Table 4 . LGE was less prevalent in patients with the simple sigmoid (27%) or neutral (25%) morphologies, in contrast to the other septal subtypes. Similarly, the mass of the left ventricle occupied by LGE was higher for apical (5.0 + 2.2%) and catenoid (2.3 + 2.4%) subtypes than the simple sigmoid morphology (0.9 + 2.2%).
In multivariate analysis, only presence of the catenoid septal configuration (OR 6.57, 95% CI 1.50, 28.80) and maximum LV wall thickness by magnetic resonance imaging (OR 1.21; 95% CI 1.00, 1.47) were associated with the presence of LGE, after adjustment for LV mass and LV outflow tract gradient ( Table 5) .
Clinical outcome
During a mean follow-up of 45 + 32 months, 35 of 75 (47%) patients in the entire cohort received septal reduction therapy (either surgical septal myectomy or alcohol septal ablation). Twenty-five of the 46 (54%) patients with catenoid, 7 of 22 (30%) of sigmoid, and 3 of 4 (75%) of neutral subtypes had septal reduction therapy due to symptoms refractory to medical management. Implantable cardioverter-defibrillators were placed in 13 of 75 (17%) of the cohort during follow-up. Thirteen of 46 (28%) patients with the catenoid subtype underwent ICD implantation while no patients with other forms of HCM underwent ICD implantation. ICDs were implanted in 11 patients for primary prevention indications (presence of risk factors for sudden death in HCM), and two were implanted for secondary prevention following an episode of sustained VT. The mean number of SCD risk factors in these patients was 2.2 + 0.6. Aborted cardiac death (sustained VT or ventricular fibrillation by ICD interrogation) occurred in 4 of the 11 primary prevention patients during follow-up.
Discussion
HCM is associated with a considerable phenotypic heterogeneity in morphologic and clinical presentations. Differences in septal morphology have been noted in this condition for decades, 1 -3 but there has been no accepted classification system for the appearance of the patterns of hypertrophy in HCM. The results of the current study describe a reproducible classification scheme for septal morphology that is based on standard transthoracic echocardiographic views. Moreover, septal morphology was found to be associated with significant differences in clinical features and outcome of HCM, with features of adverse prognosis for patients with catenoid subtypes. This information may, eventually, aid in risk-stratification and triage in this patient population.
Earlier studies have suggested that septal shape may be associated with haemodynamic features 2 or gene mutations. 4, 5 More than 25 years ago, Wigle score was proposed as an echocardiographic point-scoring system to incorporate site and extent of septal hypertrophy, but this score has been associated with haemodynamic measurements only. 2 Recently, Binder et al. 4 reported on the association between myofilament mutations and septal configuration in HCM patients who were qualitatively categorized into one of four morphologies, similar to those in this study. However, we found it difficult to reproducibly classify patients based on qualitative appearance alone, which prompted the algorithm and semi-quantitative criteria reported herein. For example, in the LAX view, some catenoid subtypes approximate a simple sigmoid septum because of the prominent basal, subaortic hypertrophy. However, from the apical four-chamber view (i.e. angled more posteriorly), the mid-septal bulge is obvious and 13 have reported an association between increased LV mass determined by CMR and a higher rate of HCM-related death. Whereas the amount of LGE in our study population is somewhat lower than that reported by other groups, the overall prevalence of LGE is strikingly similar. 14, 15 These findings are of particular interest given recent data which have linked the presence of LGE by CMR to the burden of ventricular arrhythmia in HCM. 15 -17 Consistent with this observation, a higher rate of ICD implantation for primary prevention of SCD was observed in our study during follow-up among patients with catenoid septal morphologies, including 4 of 11 (36%) who subsequently had aborted sudden death events. With regard to symptoms related to HCM, there were no statistically significant differences across septal subtypes, although patients with catenoid had the highest percentage of NYHA 3 or 4 symptoms. By Doppler echocardiography, the presence of restrictive (grade 3) diastolic dysfunction was almost exclusively seen among patients with catenoid morphologies. This may be due a combination of the high LV mass and LGE (i.e. myocardial fibrosis) found in these patients. Recent studies have described an association between the catenoid, or reverse sigmoid, septal morphology, higher frequency of myofilament protein gene mutations, and worse left ventricular systolic and diastolic function in HCM. 4, 18 In addition, in our patients with catenoid or neutral septal subtypes, the resting LVOT gradient was higher. In follow-up, a high rate of septal reduction therapy among these groups was observed, reflecting their advanced symptoms and high resting and provocable outflow tract gradients. The relationship between myofilament protein mutation and the different septal morphologies was not evaluated in the present study, but a previous study has described the highest frequency of any sarcomeric mutation in the reverse sigmoid subtype. 4 In this study, the distribution of associated genes was similar across the different septal morphologies, suggesting that the presence of any myofilament protein mutation may influence septal anatomy as well as the clinical characteristics of the disease. This study has several limitations. The study cohort was evaluated at a single referral centre and the patient characteristics are not reflective of HCM in the general population, particularly the percentage of patients with advanced symptoms. Similarly, the proportions of each septal morphology may differ within other cohorts. Septal morphologies were classified using images available at the time of enrolment into the study cohort, although it is unlikely that an individual's septal anatomy varies over time. Delineation of the basal region of the interventricular septum was based on the approximation of the anterior MV leaflet at end-diastole. Although abnormalities of MV anatomy are well-recognized in HCM, including elongated MV leaflets, 19 no differences in mitral annular and AMVL heights or their ratio were found across the septal sub-groups. Although this classification system does not take into account hypertrophy at other sites besides the septum, its focus on the septum makes it simple and reproducible, while still partitioning clinically relevant features.
In conclusion, the results of our study describe a simple, reproducible classification system of septal morphologies in HCM using conventional two-dimensional echocardiography. This proposed classification is supported by important clinical associations between septal morphology and clinical outcome of HCM in our cohort, with characteristics of advanced disease among patients with catenoid septal anatomy. Future studies should seek to confirm the utility of this classification system, particularly its association with outcome or response to therapies in this condition.
